# Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

> **NCT05641935** · PHASE2 · RECRUITING · sponsor: **john eisenbrey** · enrollment: 210 (estimated)

## Conditions studied

- Recurrent Renal Cell Carcinoma
- Renal Cell Carcinoma

## Interventions

- **DRUG:** Sulfur Hexafluoride Lipid Microspheres
- **PROCEDURE:** Contrast-Enhanced Ultrasound
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Electronic Health Record Review

## Key facts

- **NCT ID:** NCT05641935
- **Lead sponsor:** john eisenbrey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-03
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641935, "Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05641935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*